TD-HY373026

Datopotamab(TD-HY373026) is a research-grade recombinant antibody targetingPancreatic carcinoma marker protein GA733-1. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.

Human

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Humanized

IgG1-kappa

Monoclonal

Pancreatic carcinoma marker protein GA733-1, Tumor-associated calcium signal transducer 2, M1S1, TROP2, TACSTD2, Cell surface glycoprotein Trop-2, GA733-1, Membrane component chromosome 1 surface marker 1

Please contact the lab for this information.

>95% purity as determined by SDS-PAGE.

Protein A/G purified from cell culture supernatant.

P09758

Liquid

0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

DS-1062, DS-1062a, Datopotamabderuxtecan, 2267989-53-5

Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab is used for the synthesis of antibody-drug conjugates (ADC) drugs. Antibody-drug conjugates with sacituzumab (sacituzumab govitecan) targeting TROP-2 have been approved for the field of triple-negative breast cancer.• RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models., PMID:27582525• Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics., PMID:19088204

Detects Human TROP2 in indirect ELISAs.　　|　SDS-PAGE for Research Grade Datopotamab.　　|　Flow-cytometry using anti-human TACSTD2 antibody. Untransfected cells (blue Histogram) and Transfected cells (Yellow Histogram) were stained with an anti-human TACSTD2 monoclonal antibody (Catalog: HY373026) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a Goat Anti-Human IgG H&L Polyclonal Antibody, FITC (abinScience: HF690414) and cells analysed on a NovoCyte Flow Cytometer.　　|　Western blot analysis was performed using anti-TACSTD2/TROP2 monoclonal antibody at 1μg/ml on various samples.Lane 1:recombinant human TACSTD2/TROP2 (Catalog No:TD-HY373011)　　|　Flow-cytometry using FITC anti-human TACSTD2 antibody. Hela cells were stained with an irrelevant antibody (Blue Histogram) or an FITC anti-human TACSTD2 monoclonal antibody (Catalog HY373026, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, and cells analysed on a NovoCyte Flow Cytometer. ### Flow-cytometry using FITC anti-human TACSTD2 antibody. MCF7 cells were stained with an irrelevant antibody (Blue Histogram) or an FITC anti-human TACSTD2 monoclonal antibody (Catalog HY373026, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, and cells analysed on a NovoCyte Flow Cytometer.

For research use only. Not suitable for clinical or therapeutic use.